X4 Pharmaceuticals, Inc. (XFOR) is a Biotechnology company in the Healthcare sector, currently trading at $4.20. It has a SharesGrow Score of 53/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is XFOR = $10 (+138.1% upside).
Valuation: XFOR trades at a trailing Price-to-Earnings (P/E) of -5.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.06.
Financials: revenue is $35M, +1273.2%/yr average growth. Net income is $79M (loss), growing at -18.8%/yr. Net profit margin is -225.6% (negative). Gross margin is 82.2% (+13.4 pp trend).
Balance sheet: total debt is $77M against $186M equity (Debt-to-Equity (D/E) ratio 0.41, conservative). Current ratio is 10.16 (strong liquidity). Debt-to-assets is 26.6%. Total assets: $290M.
Analyst outlook: 12 / 13 analysts rate XFOR as buy (92%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 88/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).
